280 related articles for article (PubMed ID: 28636622)
1. Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.
Guillot C; Martel N; Berby F; Bordes I; Hantz O; Blanchet M; Sureau C; Vaillant A; Chemin I
PLoS One; 2017; 12(6):e0179697. PubMed ID: 28636622
[TBL] [Abstract][Full Text] [Related]
2. Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection
Beilstein F; Blanchet M; Vaillant A; Sureau C
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212929
[TBL] [Abstract][Full Text] [Related]
3. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro.
Noordeen F; Vaillant A; Jilbert AR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5291-8. PubMed ID: 23939902
[TBL] [Abstract][Full Text] [Related]
4. Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells.
Real CI; Werner M; Paul A; Gerken G; Schlaak JF; Vaillant A; Broering R
Sci Rep; 2017 Mar; 7():43838. PubMed ID: 28272460
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells.
Blanchet M; Sinnathamby V; Vaillant A; Labonté P
Antiviral Res; 2019 Apr; 164():97-105. PubMed ID: 30771404
[TBL] [Abstract][Full Text] [Related]
6. Activity of nucleic acid polymers in rodent models of HBV infection.
Schöneweis K; Motter N; Roppert PL; Lu M; Wang B; Roehl I; Glebe D; Yang D; Morrey JD; Roggendorf M; Vaillant A
Antiviral Res; 2018 Jan; 149():26-33. PubMed ID: 29126900
[TBL] [Abstract][Full Text] [Related]
7. Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection.
Vaillant A
Antiviral Res; 2016 Sep; 133():32-40. PubMed ID: 27400989
[TBL] [Abstract][Full Text] [Related]
8. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
[TBL] [Abstract][Full Text] [Related]
9. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
[TBL] [Abstract][Full Text] [Related]
10. Anti-hepatitis B virus activities of α-DDB-FNC, a novel nucleoside-biphenyldicarboxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice.
Yang Q; Zhao X; Zang L; Fang X; Zhao J; Yang X; Wang Q; Zheng L; Chang J
Antiviral Res; 2012 Dec; 96(3):333-9. PubMed ID: 23098744
[TBL] [Abstract][Full Text] [Related]
11. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.
Noordeen F; Vaillant A; Jilbert AR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5299-306. PubMed ID: 23939904
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.
Isorce N; Testoni B; Locatelli M; Fresquet J; Rivoire M; Luangsay S; Zoulim F; Durantel D
Antiviral Res; 2016 Jun; 130():36-45. PubMed ID: 26971407
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro.
Boulon R; Blanchet M; Lemasson M; Vaillant A; Labonté P
Antiviral Res; 2020 Nov; 183():104853. PubMed ID: 32585322
[TBL] [Abstract][Full Text] [Related]
14. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes.
Huang HC; Tao MH; Hung TM; Chen JC; Lin ZJ; Huang C
Antiviral Res; 2014 Nov; 111():100-11. PubMed ID: 25260897
[TBL] [Abstract][Full Text] [Related]
15. Viral and cellular determinants involved in hepadnaviral entry.
Glebe D; Urban S
World J Gastroenterol; 2007 Jan; 13(1):22-38. PubMed ID: 17206752
[TBL] [Abstract][Full Text] [Related]
16. Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis.
Lam WY; Leung KT; Law PT; Lee SM; Chan HL; Fung KP; Ooi VE; Waye MM
J Cell Biochem; 2006 Mar; 97(4):795-812. PubMed ID: 16237706
[TBL] [Abstract][Full Text] [Related]
17. Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban S; Bartenschlager R; Kubitz R; Zoulim F
Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.
Noordeen F; Scougall CA; Grosse A; Qiao Q; Ajilian BB; Reaiche-Miller G; Finnie J; Werner M; Broering R; Schlaak JF; Vaillant A; Jilbert AR
PLoS One; 2015; 10(11):e0140909. PubMed ID: 26560490
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
